ABBV vs MCK
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. MCK: A global leader in pharmaceutical distribution and healthcare technology services, connecting biopharma, providers, and patients to improve care outcomes.
Side-by-side fundamentals
| Metric | ABBV | MCK | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $264.52 | $873.79 | |
| Market cap as of 2026-08-24 | $467.4B | $101.9B | |
| P/E as of 2026-08-24 | 74.32 | 23.40 | MCK lower |
| PEG as of 2026-08-24 | 6.59 | 1.70 | MCK lower |
| Net margin as of 2026-08-24 | +9.8% | +1.1% | ABBV higher |
| Gross margin as of 2026-08-24 | +72.8% | +3.6% | ABBV higher |
| Operating margin as of 2026-08-24 | +26.2% | +1.6% | ABBV higher |
| ROE as of 2026-08-24 | +95.6% | +39.4% | ABBV higher |
| ROA as of 2026-08-24 | +4.7% | +5.4% | MCK higher |
| Debt / equity as of 2026-08-24 | 49.22 | 1.29 | MCK lower |
| Revenue growth (YoY) as of 2026-08-24 | +10.4% | +8.8% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +13.4% | MCK higher |
| Dividend yield as of 2026-08-24 | +4.5% | +0.5% | ABBV higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.27 | 0.05 | |
| 1-year return as of 2026-08-24 close | +25.6% | +26.7% | MCK higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.